Result of AGM

RNS Number : 1866Z
Verici Dx PLC
19 May 2021
 

Verici Dx plc

("Verici Dx" or the "Company") 

 

Result of AGM

 

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, announces that at today's Annual General Meeting ("AGM") held earlier today, all resolutions were duly passed.

 

The results of the AGM will be made available on the Company's website: https://vericidx.com/

 

Enquiries:

 

Verici Dx

www.v ericidx .com

Sara Barrington, CEO 

Via Walbrook PR

Julian Baines, Chairman

 


 

N+1 Singer (Nominated Adviser & Broker)

Tel: 020 7496 3000

Aubrey Powell / Justin McKeegan / Tom Salvesen

 


 

Walbrook PR Limited

Tel: 020 7933 8780 or  vericidx@walbrookpr.com

Paul McManus / Sam Allen

Mob: 07980 541 893 / 07748 651 727

 

About Verici Dx plc www.vericidx.com

Verici Dx is developing and commercialising tests to understand how a patient will and is responding to organ transplant, with an initial focus on kidney transplants. The body's own immune system poses a threat to a successful transplant or graft. Patients' immune systems differ in how they respond to the presence of the transplanted organ, characterising this response is called immune phenotyping. Our products and solutions are underpinned by extensive scientific research into the recipient's immune phenotype and how that impacts on acute rejection, chronic injury and ultimately failure of the transplant. These immuno-profile signatures also inform clinicians as to the optimal strategy for immunosuppressive and other therapies for the most successful treatment to ensure graft acceptance with the least amount of side effects.

 

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RAGBSGDUXBBDGBC

Companies

Verici DX (VRCI)
UK 100

Latest directors dealings